{"organizations": [], "uuid": "1a1eff5553b9df805bc418dcab651629a5939c94", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://s.marketwatch.com/public/resources/MWimages/MW-FW709_celgen_ZG_20171020105449.jpg", "site_section": "", "section_title": "", "url": "https://www.wsj.com/articles/celgene-nears-deal-to-buy-impact-biomedicines-for-as-much-as-7-billion-1515353759", "country": "US", "domain_rank": 387, "title": "Celgene said to be near $7 billion deal to buy Impact Biomedicines - MarketWatch", "performance_score": 0, "site": "wsj.com", "participants_count": 0, "title_full": "", "spam_score": 0.047, "site_type": "news", "published": "2018-01-07T20:14:00.000+02:00", "replies_count": 0, "uuid": "1a1eff5553b9df805bc418dcab651629a5939c94"}, "author": "Jonathan D. Rockoff", "url": "https://www.wsj.com/articles/celgene-nears-deal-to-buy-impact-biomedicines-for-as-much-as-7-billion-1515353759", "ord_in_thread": 0, "title": "Celgene said to be near $7 billion deal to buy Impact Biomedicines - MarketWatch", "locations": [], "entities": {"persons": [{"name": "marketwatch", "sentiment": "negative"}, {"name": "landov mark alles", "sentiment": "none"}, {"name": "dana cimilluca ben dummett", "sentiment": "none"}], "locations": [{"name": "beverly hills", "sentiment": "none"}, {"name": "n.j.", "sentiment": "none"}, {"name": "san diego", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "bloomberg news", "sentiment": "negative"}, {"name": "celgene", "sentiment": "negative"}, {"name": "celgene celg", "sentiment": "none"}, {"name": "impact biomedicines", "sentiment": "none"}, {"name": "celgene corp.", "sentiment": "none"}, {"name": "food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Celgene Corp. agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion.\nCelgene will make an upfront payment of $1.1 billion for the privately held San Diego company, the companies said in a statement Sunday, confirming an earlier report in The Wall Street Journal.\nAssuming Impact hits regulatory-approval... ", "external_links": [], "published": "2018-01-07T20:14:00.000+02:00", "crawled": "2018-01-08T02:05:53.001+02:00", "highlightTitle": ""}